V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
